Podcasts about Patina

Marathon and Birdie make some impulsive decisions and the Patina races their hearts out.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Cardiff Indoor Market by odilonmarcenaro. Link & License. - Hypocritopotamus by Doctor Turtle. Link & License. - Today's Special: Jam Tomorrow by Doctor Turtle. Link & License. - Remember Alexis Zorbas (ID 1340) by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Caroline and Liz welcome New York-based designer and author Brittany Bromley, known for her traditional interiors with layered patterns. Brittany shares insights from her new book, 'Relaxed Elegance,' and the inspiration behind her use of antique aesthetics mixed with luxurious details. Brittany also discusses her own home renovation and her design process, including the courageous use of patterns, colors, and textures in her projects. From transforming neglected homes to crafting customized room designs, Bromley's work reflects a mix of elegance and lived-in comfort, tailored to the personalities and needs of her clients. What You'll Hear This Episode: 00:00 Introduction to the Podcast 00:34 Meet Brittany Bromley: Designer and Author 01:18 Brittany's Home: A Designer's Vision 04:13 The Dining Room Transformation 12:29 The Art of Pattern Mixing 24:37 Bridge Hampton Residence: Humor and Tradition 27:19 Designing Double-Height Living Rooms 31:54 The Impact of a Large Window 32:20 Incorporating Color in Neutral Spaces 32:54 Choosing Muted Colors 34:09 The Role of Patterns and Textures 37:19 The Evolution of Textile Design 39:34 The Versatility of Natural Fiber Rugs 40:58 Creating Relaxed Elegance 42:11 The Importance of Patina and Layering 43:42 Using Marble in Kitchens 48:46 Balancing Cool and Warm Colors 51:58 Designing for Different Locations 53:39 The Rise of Performance Textiles 55:59 Conclusion and Final Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

Drs. Callahan and Yuan discuss data presented at ASCO 2025 on DESTINY-Breast09, PATINA, and MINI Trial, the utility of PFS-2 as an endpoint, and sequencing of treatments after first-line therapy.

The Patina spends quality time in pairs during their last bit of free time.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Challk Writing - Slow.wav by PsychoPancake. Link & License. - Declaration of My Love by Squire Tuck. Link & License. - That Guy's Sky Is Way Too High (long version) by Doctor Turtle. Link & License. - NEONBULA.mp3 by P C III. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Ens Patina l'Embrague és un magazine radiofònic pensat, conduït i produït per persones amb problemes de salut mental que, a més d'oferir un rigor informatiu i uns continguts d'interès, treballa competències bàsiques, transversals i de comunicació, contribuint a la lluita contra l'estigma social del colꞏlectiu i la sensibilització vers la salut mental. podcast recorded with enacast.com

This week the boys sit down talk about the newly crowned Stanley Cup champion Florida Panthers, a little football and basketball. Then a nice Father's Day recap. We also touched on the conflict with Iran and Israel on the current events side of things. This all went down while we enjoyed the recently released year of the snake from Rocky PatelPatrol Gone Wild brings us a breakdown of one of the LA riot clips, a taser deployment, and a criminal with more than questionable court room attire.Caleb brings us news this week with a release announcement from Cavalier. A new collab from Patina and Viso Horny. Then a new expression from YellowstoneCigar: Rocky Patel Year Of The SnakeWhiskey: Catchers RyeA huge thank you to our show sponsors Crowned Heads Cigars, Dunbarton Tobacco and Trust, and Small Batch Cigars! Make sure you're checking them out for all of your cigar needs!https://www.crownedheads.comhttps://www.dunbartoncigars.comhttps://www.smallbatchcigar.comUse Code "HERF" For 10% off your order (Some Exclusions Apply) SUBSCRIBE TO OUR YOUTUBE CHANNEL AND WATCH ALL OF OUR EPISODES IN STUDIO!Join The After Herf Show on Patreon Now!Patreon: https://www.patreon.com/DownToHerfPodcastVisit our Social Media Pages for News and More!Instagram: https://www.instagram.com/downtoherfpodcast/Facebook: https://www.facebook.com/downtoherfpodcast/

What if the very parts of yourself you've been hiding—the messy, the marvelous, the unspoken—are the ones that will set you free in midlife? We're often told to shrink, to quiet down, to accept invisibility, like it's a rite of passage. But what if this chapter is actually about expansion, revealing more of who we are, not less? Because let's be honest, midlife women are not a monolith. We're complex, multifaceted, full of rage and tenderness, reinvention and regret, humor and heartbreak. So many of those parts don't get revealed until we find the courage to tell our stories. That's when the magic happens. That's when we feel seen, heard, validated, and we realize we were never alone.Reclaim your sensuality and step into a powerful new chapter. The Midlife Pleasure Collective is a monthly membership designed to help midlife women reconnect with their bodies, embrace their desires, and cultivate deeper pleasure.Dina Aronson is a writer, editor, and pro-age advocate who is passionate about shining a light on midlife women and reframing the cultural conversation around aging. She began her career as an attorney, later founding a legal search consultancy, but pivoted as she approached midlife and couldn't find relevant content that reflected her experience. She began freelancing for start-ups aimed at the forty and above woman, and founded the Patina blog, now a Substack newsletter called Patina with Dina Aronson, where she explores topics in and around aging through her midlife lens. Highlights from our discussion include:Midlife is not about shrinking or becoming invisible, but about expanding and revealing more of your authentic self.Midlife women are complex and multifaceted, defying simple stereotypes or categorization.Courage to share our stories is transformative, allowing us to be truly seen and understood.Our hidden or unspoken parts—including emotions like rage, tenderness, regret, and humor—are sources of power, not weakness.Sharing our experiences helps us realize we are not alone in our midlife journey, creating connection and validationIn midlife, our power lies not in conforming to societal expectations, but in embracing our full, messy, magnificent selves—and having the courage to share those stories that make us beautifully, unapologetically human.If you're seeking to reclaim your pleasure and vitality, join Gabriella at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.pleasureinthepause.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for this enlightening journey into the heart of female pleasure and empowerment.CONNECT WITH DINA ARONSON:Midlife Private PartsSubstack - Patina with Dina AronsonInstagram - Patina_LifeCONNECT WITH GABRIELLA ESPINOSA:InstagramLinkedInWork with Gabriella! Reclaim your sensuality and step into a powerful new chapter. The Midlife Pleasure Collective is a monthly membership designed to help midlife women reconnect with their bodies, embrace their desires, and cultivate deeper pleasure. Join the founding members for just $20/month - spots are limited, so apply now at pleasure-in-the-pause.com/collective. Full episodes on YouTube.

This week on Episode 393, the boys gear up for Blend & Barrel this Thursday and a sizzling private dinner with Skip Martin on July 5th. Mike dives into a wild takedown by Simply Stogies—apparently their aftershow is better than the interview! We cover massive stories: U.S. strikes Iran's nuclear site, Tesla drops robotaxis in Austin, and Kevin Durant's shocking trade to Houston. Plus, Nicaragua slams the brakes with new speed limits, Davidoff slows production, and spicy new cigars from Patina and 601 La Bomba. Two reviews. One warhead. All hustle.

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

The Patina wraps up their heist at Ramp Girl HQ.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Pampa Salitrera » Stones tossed in the desert by Diegolar. Link & License. - fax.wav by LG. Link & License. - Labyrinth by Sergey Cheremisinov. Link & License. - A Hard Reality by The Oracle Of St. Vincent. Link & License. - What Is It I Know by The Oracle Of St. Vincent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Ens Patina l'Embrague és un magazine radiofònic pensat, conduït i produït per persones amb problemes de salut mental que, a més d'oferir un rigor informatiu i uns continguts d'interès, treballa competències bàsiques, transversals i de comunicació, contribuint a la lluita contra l'estigma social del colꞏlectiu i la sensibilització vers la salut mental. podcast recorded with enacast.com

Welcome to a special episode with our first Overseasoned Podcast guest since the pandemic, Geoff Feder of Feder Knives. Yes, we talk knives... but it's so much more than that. You can expect a entertaining rundown of the Triple P's: Patina, Pineapple, Paella. You won't want to miss this one. There may or may not be a special giveaway involved...

O Lado B gira a Roleta da Pistolagem para comentar alguns dos principais assuntos da semana. A fuga de Zambelli e o que isso pode significar para os bolsonaristas; a Quaest divulga pesquisas que preocupam o Governo Lula III (e o Brasil); no Rio, Eduardo Paes e PT se estranham na pauta da Guarda Municipal armada enquanto Claudio Castro e Washington Reis disputam protagonismo tendo as eleições de 2026 como pano de fundo.

Adrian Molitor knows a thing or two about hardwood floors. With his Madison-based business, Molitor Traditional Flooring, he’s restored historic floors in some of southern Wisconsin’s most iconic homes and businesses. Jess Miller caught up with Molitor to talk about why the old, weathered wood speaks to him.

The Patina kicks off their heist against Ramp Girl HQ.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Dry grinds 3.wav by crazy_freerider. Link & License. - Meadow Walz (ID 1337) by Lobo Loco. Link & License. - Live-It (instrumental) by Ketsa. Link & License. - Running Eiskrokodil (ID 01) - Remastered by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Ens Patina l'Embrague és un magazine radiofònic pensat, conduït i produït per persones amb problemes de salut mental que, a més d'oferir un rigor informatiu i uns continguts d'interès, treballa competències bàsiques, transversals i de comunicació, contribuint a la lluita contra l'estigma social del colꞏlectiu i la sensibilització vers la salut mental. podcast recorded with enacast.com

Bienvenidos a este podcast donde se abordarán los temas de mayor interés en el ámbito oncológico para Latinoamérica. A lo largo de este proyecto los Dres. Diego Ballén y Mauricio Lema, oncólogos clínicos colombianos, entrevistarán a un invitado especial para abordar con base en evidencia científica y a su experiencia a aquellas interrogantes que llegan a surgir diariamente en la práctica clínica.Durante este episodio el Dr. Carlos Alberto Vargas, oncólogo clínico adscrito al CETIC, la Fundación Santa Fe y la Clínica del Country en Bogotá, Colombia, discutió en conjunto con nuestros coordinadores sobre el tratamiento del cáncer de mama.Con base en su experiencia, el Dr. Vargas respondió a las siguientes interrogantes:¿Cuál es el impacto clínico del estudio PATINA y qué tan aplicable es en la práctica inmediata?¿Qué aspectos deben considerarse sobre la toxicidad de palbociclib en combinación con doble bloqueo HER2?Si no existieran restricciones regulatorias, ¿es razonable adoptar la estrategia propuesta por PATINA en pacientes con enfermedad triple positiva?¿Cómo influye el análisis actualizado de Oncotype DX presentado en San Antonio en la decisión de uso de antraciclinas o taxanos?¿Qué valor tienen los resultados del estudio INSEMA respecto a la omisión del ganglio centinela en pacientes seleccionadas?¿Cómo aplicaría el protocolo del INSEMA en pacientes premenopáusicas?¿Qué limitaciones existen en la calidad de la ecografía axilar como herramienta de estadificación en la práctica clínica local?Según el consenso de St. Gallen, ¿cuál es el papel actual de los inhibidores CDK4/6 en adyuvancia a partir de los estudios monarchE y NATALEE?¿Qué relevancia tiene el análisis preliminar del estudio KEYNOTE-756 y cómo se posiciona la inmunoterapia neoadyuvante en pacientes luminales B con baja expresión hormonal?¿Cuáles son las controversias actuales en torno al tratamiento adyuvante con inmunoterapia en pacientes con cáncer de mama triple negativo y tumores pequeños tratados con cirugía inicial? Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país. Fecha de grabación: 19 de marzo de 2025.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

„Wenn Deutschland niest, schüttelt es Österreich“: Diesen Satz sagt mir Walter Senk bei unserem Spaziergang durch den 7. Bezirk von Wien. Wie gerade im Intro gehört, habe ich mit ihm über eine der größten Immobilien-Pleiten gesprochen. Walter Senk ist Herausgeber und Chefredakteur der „Unabhängigen Immobilienredaktion“, seit 27 Jahren in der Immobilienbranche in Österreich unterwegs und sehr fest verankert. Walter fängt mit den positiven Signa-Dingen an, die da heißen: sehr gute Projekte umgesetzt, Visionen gehabt für eben jene Projekte, die niemand sonst hatte, ein kompetentes Team. Wir sprechen aber auch über die derzeitige Situation der Immobilienbranche in Österreich. Im Wohnsegment ist er komplett anders, weil ein Großteil gedeckelt ist. Problem derzeit: kaum Neubau und Sanierungen, die Nebenkosten schließen fast zu den Mieten auf. Es geht natürlich um die Vorbildwirkung von Wien, die allerdings nun eher Patina ist. Walter erzählt, warum die KIM-Verordnung den Wohnungsmarkt fast zum Erliegen brachte, warum Verdichtungen und Aufbauten nicht funktionieren und wie er zu dem Satz kommt: „Früher waren wir eine Demokratie, heute sind wir eine Bürokratie.“ Viele Insights in den Markt der Nachbarländer mit einem echten Insider!

Patina Miller chats all about season 4 of Raising Kanan, from Raq's love life, pregnancy, and her tense relationship with her son, Kanan. Patina discusses the decision Raq made to end her pregnancy, her tumultuous relationship with Unique, and whether Raq would choose her son or her business. The season finale of Raising Kanan season 4 is airing now and Raq's life hangs in the balance. Watch the video podcast on YT: https://youtu.be/utLTBVYmvjsWill Patina Miller's Raq live to see season 5? Power Book III: Raising Kanan is streaming now on Starz, and has been renewed for its fifth and final season.Alongside Miller, Raising Kanan stars Mekai Curtis, Tony Danza, London Brown, Joey Bada$$, and more.Son of a Binge production credits:Hosted by: Reshma Gopaldas (TW: @reshingbull, IG @reshmago)Producer: Emily Collins (IG @emilem124)Artwork by: Laura Valencia (IG @iamlauravalencia)Music by: Kevin Calaba (IG @airlandsmusic)Send us a text, let us know what shows and guests you want us to cover.

The Patina does some proper heist prep for once.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Walking on Airvent.wav by SiyaMahlobo. Link & License. - Dry grinds 3.wav by crazy_freerider. Link & License. - Smiling Turtle (ID 2003) by Lobo Loco. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Ens Patina l'Embrague és un magazine radiofònic pensat, conduït i produït per persones amb problemes de salut mental que, a més d'oferir un rigor informatiu i uns continguts d'interès, treballa competències bàsiques, transversals i de comunicació, contribuint a la lluita contra l'estigma social del colꞏlectiu i la sensibilització vers la salut mental. podcast recorded with enacast.com

This week the boys are joined by Chris Rice of 10th Mountain Whiskey. Chris shares the story of the brand and allowed us to sample 10 of their expressions. This conversation then cycled back and forth from whiskey to cigars in tangents only Caleb could pull off. This all went down while we enjoyed the newly released Alma de Cielo from PlacenciaPatrol Gone Wild this week features a criminal leading police on a literal Easter egg hunt, a drug filled trip to the magic kingdom, and you guessed it another terrible teacher.Caleb's news this week brings announcements of new releases out of Patina and Montecristo. Then an all new bourbon expression from Woodenville.Cigar: Plasencia Alma Del CieloWhiskey: 10th Mountain Whiskey A huge thank you to our show sponsors Crowned Heads Cigars, Dunbarton Tobacco and Trust, and Small Batch Cigars! Make sure you're checking them out for all of your cigar needs!https://www.crownedheads.comhttps://www.dunbartoncigars.comhttps://www.smallbatchcigar.comUse Code "HERF" For 10% off your order (Some Exclusions Apply) SUBSCRIBE TO OUR YOUTUBE CHANNEL AND WATCH ALL OF OUR EPISODES IN STUDIO!Join The After Herf Show on Patreon Now!Patreon: https://www.patreon.com/DownToHerfPodcastVisit our Social Media Pages for News and More!Instagram: https://www.instagram.com/downtoherfpodcast/Facebook: https://www.facebook.com/downtoherfpodcast/

The Patina gets a new job opportunity from Opal and then scatters across the city.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Happy Greece Traveling (ID 1339) by Lobo Loco. Link & License. - Endearing Curl by Blue Dot Sessions. Link & License. - A Little World by Yusuke Tsutsumi. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The Patina is back at the races and strives to keep their heads above water.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Honda CRM 250 2 stroke dirt bike motorcycle » motorbike crm 250cc kick start rev engine.wav by martian. Link & License. - WALLA Ballpark Applause Short 05 by AshFox. Link & License. - WALLA Ballpark Applause Short 04 by AshFox. Link & License. - WALLA Ballpark Applause Short 01 by AshFox. Link & License. - Fireball Impact by EminYILDIRIM. Link & License. - Love is True by Squire Tuck. Link & License. - Won-t-Be-Stoppin by Ketsa. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Jiunn, Seth, John and Aaron discuss their review experience with the Patina LE 2024 https://developingpalates.com/reviews/cigar-reviews/team-cigar-review-patina-le-2024/

Featuring an interview with Dr Adrienne G Waks, including the following topics: The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00) Role of immunotherapy in the treatment of breast cancer (8:30) Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55) Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37) Current role of anthracyclines in the treatment of localized breast cancer (31:17) Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21) Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics: Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30) Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49) The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25) Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18) TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50) Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09) The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02) Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36) Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23) Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56) CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04) CME information and select publications

In der heutigen Folge von Phrasensport überschlagen sich die hochkarätigen Themen nur so. Vom DFB Pokalfinale und der einmaligen Chance für die Arminia aus Bielefeld sich in den Geschichtsbüchern zu verewigen gehen wir zu zwei Vereinen, die diese Saison hinter den Erwartungen geblieben sind. Die einst so geschichtsträchtige Patina von Manchester United blättert und zeigt sich im schlechtesten Ergebnis seit 35 Jahren. 35 Jahre - so alt ist keiner der deutschen U17 Weltmeister von 2023. Aber wo stecken die Weltmeister von gestern und Talente von morgen heute? wie stehen andere europäische Nationen im Vergleich da? Kai und Philipp beleuchten für euch in gewohnter ...Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen? Dann schaue auf www.kostenlos-hosten.de und informiere dich. Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.Gern unterstützen wir dich bei deiner Podcast-Produktion.

Emma has a tea party, the Patina takes two very different approaches to X Bike upgrades, and the Council continues to be a problem.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Cardiff Indoor Market by odilonmarcenaro. Link & License. - Clank 002.wav by yottasounds. Link & License. - Riot Crowd Immersed in 5.1 Take 1 by MrProfDrDickweed. Link & License. - Stuff Will Never Love You Back by Doctor Turtle. Link & License. - The Ants Built A City On His Chest by Doctor Turtle. Link & License. - Sleepers by Sergey Cheremisinov. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

In this episode, Tara Sands and Steve Yurko interview Lisa Ortiz. At 4Kids, Lisa played a ton of roles at 4Kids including Chopin in Tama and Friends, Patina in Magical DoReMi, Serenity in Yu-Gi-Oh!, Tony Tony Chopper in One Piece, Amy Rose in Sonic X, Roxanne in Ultimate Muscle, Musa, Icy and others in Winx Club and Sabrina in Pokémon. She is the current voice director of the Pokémon anime series. You can follow her online at https://www.instagram.com/lisacultjelly/?hl=en and https://x.com/Lisalisejam 4Kids Flashback is a behind the scenes podcast about the 4Kids era of television as told by the people who were actually there. 4Kids is the company that brought Pokémon, Yu-Gi-Oh!, One Piece and many other anime series to English speaking audiences. Our website is https://www.4kidsflashback.com/  Subscribe at https://www.patreon.com/4KidsFlashback for episodes one week early and ad-free plus bonus content! For merch go to https://4kids-flashback.printify.me/products  Leave us a voice message at www.Speakpipe.com/4KidsFlashback    Autographs for Charity available at https://www.ebay.com/usr/flashback4kids  Watch videos at https://www.youtube.com/@4KidsFlashback.  Disclaimer: The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent or of this podcast and/or it's hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Real Life This week, Steven got his hands dirty—literally. Between digging, yard work, and wrestling with a modem that decided to give up on life mid-game, it's been an eventful time. Speaking of games, we dove into City of Mist, where Greg has to decide: is he the "Crusty DM" or simply sporting a "healthy patina of experience"? Devon, meanwhile, is a street shark (but NOT the cartoon kind), Steven's embodying Job (maybe the biblical one?), and Ben's teenage runaway Lily Chow has freed a djinn her parents were up to no good with. Good times, until technology betrayed us. Outside of RPGs, we had a Margaritaville party (because sometimes you just need to lean into the chaos), and we gave Let's Summon Demons a solid 4/5. Meanwhile, Devon tried out Harmonies—a game in the vein of Cascadia—and highly recommends it. If you want to check it out, here's the link: Harmonies on BGG. Oh, and Devon's also been watching Daredevil: Born Again, so we'll probably hear more about that soon. Ben, on the other hand, watched Flow (IMDB), an indie Latvian/French post-apocalyptic film with animals, boats, and a slow but gorgeous vibe. Sci-fi? He says yes. Thrill ride? Not quite, but definitely worth a watch. Future or Now? Ben took a deep dive into his cosmic worldview this week, courtesy of a Substack quiz designed to help pinpoint one's beliefs about reality. Turns out, he hovers somewhere between animism, Gnosticism, and multiverse theory—because why pick just one? He also explored Emergent Materialism, the idea that consciousness and social phenomena are more than the sum of their physical parts, while Steven proudly waved the banner of Reductive Materialism: "We're all just atoms and molecules—deal with it!" Devon, ever the skeptic, leaned into Pragmatic Instrumentalism: “Do we even know what reality is?” And of course, the multiverse debate made an appearance. Do we really buy into it? We debated it all… while channeling our inner Matt Murdock. Steven also brought up some interesting research on how we misinterpret our dogs' emotions. Humans have a habit of projecting their own feelings onto their pets, leading to misunderstandings about what they actually need. Here's the study if you want to check it out. Ben, meanwhile, admitted that his labrador has him trained rather than the other way around—because, let's face it, food is the ultimate motivator. Book Club This week, we discussed To Be Taught, If Fortunate: Votum by Becky Chambers. Topics ranged from chirality and molecular handedness to the ultimate decision-makers in the universe. Steven had thoughts about the book's ending… and let's just say he made sure we all heard them. Repeatedly. Next week, we're diving into three stories by Scott Base: The Giving Man, Scour, and Hell and Back (watch here). If you want to read along, now's your chance! That's it for this episode! Let us know your thoughts, especially if you have strong opinions on RPG archetypes, cosmic worldviews, or whether your dog is secretly running your life. Catch you next time!  

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapiesTreatment sequencing and preferred treatment options in patients with brain metastasesResults from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancerThoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trialProgram faculty:Stephanie L. Graff, MD, FACP, FASCODirector of Breast Oncology, Brown University HealthCo-Lead, Breast Cancer Translational Disease Research GroupLegorreta Cancer Center at Brown UniversityAssociate Professor of MedicineWarren Alpert Medical School of Brown UniversityProvidence, Rhode IslandLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

The Patina discusses integrity and the Sasnak political landscape continues to change.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Breezy city amb.wav by patchen. Link & License. - The Circles I Went Round In by Doctor Turtle. Link & License. - Over the Water, Humans Gather by Doctor Turtle. Link & License. - Big Water by Sergey Cheremisinov. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The Patina makes some relationship decisions.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - 06775 flatbed scanner.wav by Robinhood76. Link & License. - Inside the Moon by Stephan Siebert. Link & License. - Kerchingless by Doctor Turtle. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Listen in as we welcome Mo Maali from Patina Cigars to Episode 274 of HBTC Live! We talk about Patina Cigars, and much more!   Visit our website, follow us on Facebook, Instagram, and subscribe to our YouTube Channel. #HBTCigar #HowBoutThatCigar #Cigars #PremiumCigars #CigarPodcast #CigarShow #HBTCLive #PremiumTobacco #CigarLife #CigarCulture #BOTL #SOTL #ISmokeCigars #BurnCigarsNotBridges

The Patina reunites and tries to get back to normal.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Dripping (Zoom) » Dripping, Slow, A.wav by InspectorJ. Link & License. - pager-1 by __flederwiesel__. Link & License. - Breathe Again by BlackTrendMusic. Link & License. - What Is It I Know by The Oracle Of St. Vincent. Link & License. - A Hard Reality by The Oracle Of St. Vincent. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

In this episode of the Oncology Brothers podcast, Drs. Rohit and Rahul Gosain welcome Dr. Sarah Sammons from Dana-Farber Cancer Institute to discuss the treatment landscape for HER2-positive breast cancer. Building on their previous discussions about triple-negative breast cancer, Drs. Gosain and Sammons dive deep into the treatment algorithms for early-stage, locally advanced, and metastatic HER2-positive breast cancer. Key topics include: •⁠  ⁠Treatment paradigms for early-stage HER2-positive breast cancer, including the APT trial and considerations for neoadjuvant therapy. •⁠  ⁠The standard of care for locally advanced disease with TCHP and managing associated toxicities. •⁠  ⁠Insights into the latest data from the PATINA trial and its implications for metastatic HER2-positive patients. •⁠  ⁠Discussion on the use of T-DXd and other treatment options in the second and third-line settings, especially for patients with brain metastases. Join us for an informative conversation filled with clinical pearls and practical insights that can help guide treatment decisions in HER2-positive breast cancer. Don't forget to like, subscribe, and check out our other episodes in the treatment algorithm series! #OncologyBrothers #HER2Positive #BreastCancer #BreastCancerTreatment #CancerPodcast #DanaFarber YouTube: https://youtu.be/_y0xSxJTptw Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

The Patina receives some help from the Foundlings in their respective journeys.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - Cardiff Indoor Market by odilonmarcenaro. Link & License. - Dead Dad C by Stephan Siebert. Link & License. - Endearing Curl by Blue Dot Sessions. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

Fr. Ben serves up a small lesson on patina. He teaches what it is physically and how it can apply to one's spiritual life. Take a listen and learn. Got a question you'd like to ask Fr. Ben? Go to Ask Fr. Ben | St. Michael Church (stmichaelmemphis.org) to submit questions and topic ideas for the podcast. The questions can be on faith or food! You can also follow us on Facebook and YouTube at Soul Food Priest. Thanks for listening!

The Patina continues to make their way out of the Guts and splits the party again.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - That Guy's Sky Is Way Too High (long version) by Doctor Turtle. Link & License. - Easy - Easy by Crowander. Link & License. - Flies On The Prize by Doctor Turtle. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The boys are back after being banned by YouTube! We discuss the drawbacks of YouTube's new censorship model. How it effected our channel and how it applies to other content creators. This all went down while we enjoy the La Flor Dominicana 30th Anniversary. Patrol Gone Wild this week brings us a Wisconsin couple getting down and dirty in a laundromat, a Brad Pitt AI scam, and a Hooters girl willing to do annnyyything to get out of trouble. Caleb's back with news this week with a packaging update from La Aurora, a new release from Patina, and lastly a new expression from Sagamore. Cigar: LFD 30th Anniversary Whiskey: Wyoming Whiskey National Parks # 3 Cigars and whiskey were purchased by Down To Herf Podcast. A huge thank you to our show sponsors Crowned Heads Cigars, Dunbarton Tobacco and Trust, and Small Batch Cigars! Make sure you're checking them out for all of your cigar needs! https://www.crownedheads.com https://www.dunbartoncigars.com https://www.smallbatchcigar.com Use Code "HERF" For 10% off your order (Some Exclusions Apply) SUBSCRIBE TO OUR YOUTUBE CHANNEL AND WATCH ALL OF OUR EPISODES IN STUDIO! Join The After Herf Show on Patreon Now! Patreon: https://www.patreon.com/DownToHerfPodcast Visit our Social Media Pages for News and More! Instagram: https://www.instagram.com/downtoherfpodcast/ Facebook: https://www.facebook.com/downtoherfpodcast/

In this episode, I'm thrilled to welcome Dr. Tiffany Troso, a medical oncologist with over 25 years of experience in treating breast and gynecological cancers. We'll unpack some of the most important updates from this year's San Antonio Breast Cancer Symposium (SABCS) in a way that's clear and easy to follow. We'll cover topics like the latest on SERDS and how they're changing treatment options, the practice-changing findings from the PATINA trial, and exciting progress on a TNBC vaccine. Dr. Troso also sheds light on the growing movement toward treatment de-escalation and what it means for creating more personalized approaches to care. This episode is packed with valuable information to help patients and advocates feel informed and prepared to navigate their health journey. A special thank you to our “Your Guide to SABCS sponsors” Lilly, Gilead, Merck, Daiichi-Sankyo and Pfizer for making this episode possible.

Participe do Pix Modalidade em: podcastbelgrado@gmail.comCrowdfunding do Elástico Mental: https://benfeitoria.com/projeto/a-volta-do-elastico-mental-1se1O Café Belgrado é parceiro KTO. Melhor lugar pra fazer sua bet: kto.bt.br - Proibido para menores de 18. Jogue com Responsabilidade.Assine o conteúdo exclusivo do Café Belgrado em www.cafebelgrado.com.br e tenha acesso a uma variedade de séries exclusivas que vão te encantar:Amanhã Vai Ser Outro Dia, O Reinado, The Next Dance: A História de Luka Doncic, Belgramadness, El Gringo, BelgraVerso, MIP Hunters, Esquema de Pirâmide, F.A.D.I.N.H.A., Wemby Watch e muitos outros conteúdos empolgantes que estão esperando por você!Aproveite o cupom: cafebelgrado em www.pholias.com.br e tenha 20% de desconto! É oferta por tempo limitado!!Canal de Reacts do Café Belgrado => https://www.youtube.com/@podcastelastico6079

Juanma Rodríguez le dedica su comentario al técnico del Atlético de Madrid

Join us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies: 1.⁠ ⁠DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease. 2.⁠ ⁠DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impact on quality of life. 3.⁠ ⁠PATINA Trial - A groundbreaking study on the use of CDK4-6 inhibitors in combination with trastuzumab and pertuzumab for ER-positive, HER2-positive breast cancer, showcasing impressive progression-free survival rates. Tune in as we unpack the implications of these studies for clinical practice and discuss the future of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates on oncology research and treatment strategies! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers For more information, visit our website: OncologyBrothers.com #OncologyBrothers #BreastCancer #SABCS2024 #TDXD #PATINA #CancerResearch #Podcast

The Patina continues having two wildly different adventures in the Guts.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - "Flag of No Country" by Julia Kent. Link & License. - Mist and Clouds by Kai Engel. Link & License. - Wherever I Lay My Hat, That's My Wife by Doctor Turtle. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The Patina hits new depths in the Guts.Cast: - Marathon Messenger is played by Penn Van Batavia. She can be found on Twitter at @acquiredchaste and in drag as horror king JOHN on Instagram at @john.is.risen. Penn is an indie TTRPG designer whose most recent work includes SLICE *IT* OUT, a grisly carving RPG about cutting pieces of yourself out to fit in. Check out faer other work at pennharper.itch.io. - Cassidy Shard is played by Sydney Whittington. She is our wonderful editor. She's also a contributing editor and occasional guest player for the Orpheus Protocol, a cosmic horror espionage actual play podcast. Find her on Twitter at @sydney_whitt. - Emma Blackwood is played by Cameron Robertson. Find her on Twitter at @midnightmusic13 and on Instagram at @reading_and_dreaming. Cameron is also a player on Tabletop Squadron, a Star Wars Edge of the Empire actual play podcast. - Birdie Foundling is played by Kit Adames. Find her on Twitter at @venusvultures. Kit is also a voice actor and writer on Elevator Pitch Podcast, a queer genre-hopping anthology podcast that can be accessed on Spotify and YouTube. - Our GM and narrator is Nick Robertson. Find him on Twitter at @alias58. Nick is also the GM for Tabletop Squadron and can also be found as a player on the Orpheus Protocol.Music & Sound Credits: - This podcast features the musical talents of Dora Violet and Arne Parrott. You can find Dora at facebook.com/doraviolett. You can find Arne at atptunes.com. - old radio Channel search sound effect by Garuda1982. Link & License. - "Sekalaiset Miscellaneous » Sähköisiä räsähdyksiä / Electrical, short crackling, cracking, hissing sounds, like short-circuit, electric fault or electric shock, a close sound" by YleArkisto. Link & License. - Sleepers by Sergey Cheremisinov. Link & License. - Faster, Sons Of Vengeance, Faster! by Doctor Turtle. Link & License. - Oldies into regae song 2 - 3_30_24, 9.53 PM by u_67poxc9zbn. Link & License.Art Credits: - The official artwork for this podcast was created by Rashed AlAkroka, who can be found on Instagram and Artstation @rashedjrs.Find Us Online: - Our Website - Twitter - Join our Patreon - Join our Discord

The husband-and-wife team of Brooke and Steve Giannetti are nothing if not multitalented. He's architect, she's a designer, but together the two of them have done a little bit of everything: from opening a shop in small-town Tennessee to creating homes for A-List celebrities to caring for a menagerie of sheep, donkeys, goats and highland cattle on their farm, Patina Meadow.  On this episode of the podcast, the Giannettis speak with host Dennis Scully about how working with animals informs both their lives and their business, how they keep clients excited over the course of a long project, and why designers should be curious about new technology—not fearful.This episode is sponsored by Loloi and Annie SelkeLINKSPatina Home & GardenDennis ScullyBusiness of Home

Being content in all things? Outdated furniture? A dirty house VS lived in? We're talking about embracing the "patina" of our homes today.Follow up on YouTube for FULL Videos: https://www.youtube.com/@homemakerchicpodcastGet luxury linens from our friends at American Blossom Linens and save 20% with code FALLCHIC20: https://americanblossomlinens.comFind chemical-free, designer-quality skincare and makeup and save 10% with the code HMC10: https://toupsandco.com/Clean, CLEAN with Branch Basics! https://branchbasics.com/ Coupon code HOMEMAKERCHICIf you enjoy wine, drink Dry Farms: https://www.dryfarmwines.com/homemakerchicBe your home's BEST interior designer with Angela's Old World Design Society. Click here for ONE WEEK FREE.Want to skill up in the kitchen? Visit cook.theelliotthomestead.com for 5 new recipes and tutorials a month! Follow us on Instagramhttps://instagram.com/homemakerchicpodcastSupport the show on Patreon and get digital downloads of both our cookbooks!https://www.patreon.com/homemakerchicpodcast